A recent analysis of prognostic factors may help identify which follicular and mantle cell lymphoma patients should be excluded from trials of single-agent rituximab therapy.
A recent analysis of prognostic factors may help identify which follicular and mantle cell lymphoma patients should be excluded from trials of single-agent rituximab therapy.
Leave a Reply